Verona Pharma ADS

  • TickerVRNA
  • ISINUS9250501064
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom
 PRESS RELEASE
VRNA Verona Pharma A... (Health Care)

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collab...

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China $40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China LONDON and RALEIGH, N.C. and SHANGHAI, China, June 10, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
VRNA Verona Pharma A... (Health Care)

Verona Pharma to Present at Jefferies Virtual Healthcare Conference

Verona Pharma to Present at Jefferies Virtual Healthcare Conference LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:00 AM ET. A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, .   Veron...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
VRNA Verona Pharma A... (Health Care)

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collab...

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China $40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China LONDON and RALEIGH, N.C. and SHANGHAI, China, June 10, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
VRNA Verona Pharma A... (Health Care)

Verona Pharma to Present at Jefferies Virtual Healthcare Conference

Verona Pharma to Present at Jefferies Virtual Healthcare Conference LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:00 AM ET. A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, .   Veron...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
VRNA Verona Pharma A... (Health Care)

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collab...

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China $40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China LONDON and RALEIGH, N.C. and SHANGHAI, China, June 10, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
VRNA Verona Pharma A... (Health Care)

Verona Pharma to Present at Jefferies Virtual Healthcare Conference

Verona Pharma to Present at Jefferies Virtual Healthcare Conference LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:00 AM ET. A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, .   Veron...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
VRNA Verona Pharma A... (Health Care)

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collab...

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China $40 million upfront including $25 million cash and $15 million in equity in Nuance Biotech (parent company) Up to $179 million in potential clinical, regulatory, and commercial milestone payments plus tiered double-digit royalties Nuance Pharma is responsible for all costs related to development and commercialization of ensifentrine in China LONDON and RALEIGH, N.C. and SHANGHAI, China, June 10, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides
 PRESS RELEASE
VRNA Verona Pharma A... (Health Care)

Verona Pharma to Present at Jefferies Virtual Healthcare Conference

Verona Pharma to Present at Jefferies Virtual Healthcare Conference LONDON and RALEIGH, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Chief Executive Officer and President, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 9:00 AM ET. A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, .   Veron...

Liana Moussatos ... (+3)
  • Liana Moussatos
  • Shveta Dighe
  • Andreas Argyrides

ResearchPool Subscriptions

Get the most out of your insights

Get in touch